* To replay the media content and watch again, please refresh your screen

In this second interactive patient case video from BREAST CANCER CONNECT, Prof. Valentina Guarneri presents a patient with ER+/HER2- metastatic breast cancer, focusing on tumour characteristics, treatment strategies, and the management of adverse events.

 

As you journey through the entire diagnostic and treatment process, you'll interact and engage with valuable information, challenging questions and clickable resources along the way.

 

Catch up on the first case study to hear Dr Elisa Agostinetto present a patient with ER+/HER2- de novo metastatic breast cancer.

 

Clinical Takeaways

 

  • Assessing tumour characteristics, including prevalent mutations like ESR1 and PIK3CA, can significantly influence and guide treatment choices in patients with ER+/HER2- metastatic breast cancer

  • Liquid biopsy, specifically blood-based ctDNA analysis, is the preferred method for detecting ESR1 mutations due to its heightened sensitivity and the avoidance of repeat biopsies at metastatic sites

  • Elacestrant, as the first FDA-approved oral SERD (January 2023), offers a promising choice for select patients with ER+/HER2-  metastatic breast cancer harbouring an ESR1 mutation

  • Oral SERDs are being studied as a monotherapy and in combination with targeted therapies (i.e. CDK4/6, PI3K and AKT inhibitors), offering promising prospects for their integration into clinical practice

"Valentina Guarneri, MD, PhD, is Full Professor of Oncology at the University of Padua, Head of the Division of Oncology 2 at the Istituto Oncologico Veneto, and head of the Specialization School in medical Oncology at the University of Padova. She completed her fellowship in Oncology in 2003, and she obtained her PhD Degree in Clinical and Experimental Oncology in 2007. In 2005 she was appointed Assistant Professor of Oncology at the University of Modena and Reggio Emilia, where she also chaired the Breast Unit. In 2005, she also completed a 6-month-research experience at the Department of Breast Medical Oncology, UT. MD Anderson Cancer Center, Houston, Texas, where in 2009 she was Visiting Assistant Professor. In 2014 she was appointed Associate Professor of Oncology at the University of Padua.  Prof Guarneri’s research interest is mainly focused on clinical and translational research for breast cancer patients. She has published more than 200 papers in peer-reviewed journals."

Prof. Valentina Guarneri has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Advisory Role: Eisai, Eli Lilly, Exact Sciences, Gilead, Merck Serono, MSD, Novartis, Olema Oncology.

Speakers bureau: Amgen, Eli Lilly, GSK, Gilead, AstraZeneca, Novartis.

Expert testimony: Eli Lilly

Programme summary
  • clock Duration 15 MIN
  • clock Language(s) flag
Other episodes in this series
Oral SERDs: New Endocrine Therapy Options in ER+ Advanced or Metastatic Breast Cancer – Part 1

Oral SERDs: New Endocrine Therapy Options in ER+ Advanced or Metastatic Breast Cancer – Part 1

An interactive patient case video series from breast cancer specialists

Oral SERDs: New Endocrine Therapy Options in ER+ Advanced or Metastatic Breast Cancer – Part 2

Oral SERDs: New Endocrine Therapy Options in ER+ Advanced or Metastatic Breast Cancer – Part 2

An interactive patient case video series from breast cancer specialists

Current Episode
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Menarini Stemline Oncology
Endorsement
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
BREAST CANCER CONNECT

BREAST CANCER CONNECT is an initiative of COR2ED, supported by an Independent Medical Educational Grant from Menarini Stemline Oncology.

Meet the experts

Other programmes of interest

Podcast
Oncology 
Colorectal cancer: understanding the needs of different patient populations

Exploring the impacts of age, ethnicity, socioeconomic status, and access to healthcare on patients with colorectal cancer

Experts
Prof. Tanios Bekaii-Saab, Deneen Richmond, Oncology Brothers (Moderators)
Endorsed by
COLONTOWN
  • download Downloadable
    Resources
  • clock 25 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Podcast
Oncology 
Interpreting real-world evidence in later-line mCRC

Aligning real-world evidence with clinical trial data 

Experts
Prof. Tanios Bekaii-Saab, Prof. Shubham Pant
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Podcast

Episode

1

of 3

episode
Oncology 
Cáncer de próstata: Dificultades en la fase preanalítica y pruebas de biomarcadores (Spanish)

Moderado por los Oncology Brothers. Episodio 1 de una serie de podcast de video de 3 partes.

Experts
Dr Alexander Wyatt, Dr Petros Grivas, Oncology Brothers (Moderators)
Endorsed by
NASPCC AMP
  • download Downloadable
    Resources
  • clock 30 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.
Podcast

Episode

3

of 3

episode
Oncology 
Câncer de Ovário: Desafios da fase pré-analítica e teste de biomarcadores (Portuguese)

Moderado pelos Oncology Brothers. Episódio 3 da série de podcasts em vídeo de 3 partes

Experts
Assoc. Prof. Martina Murphy, Assoc. Prof. Caterina Marchiò, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 32 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.
Podcast

Episode

3

of 3

episode
Oncology 
Cáncer de ovario: Dificultades en la fase preanalítica y pruebas de biomarcadores (Spanish)

Moderado por los Oncology Brothers. Episodio 3 de una serie de podcast de 3 partes.

Experts
Assoc. Prof. Martina Murphy, Assoc. Prof. Caterina Marchiò, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 32 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.
Podcast

Episode

2

of 3

episode
Oncology 
Câncer de Pulmão: Desafios da fase pré-analítica e teste de biomarcadores (Portuguese)

Moderado pelos Oncology Brothers. Episódio 2 da série de podcasts em vídeo de 3 partes

Experts
Dr Bruna Pellini, Dr Semir Vranić, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 25 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.